FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3027432980> ?p ?o ?g. }

• W3027432980 endingPage "S21" @default.
• W3027432980 startingPage "S21" @default.
• W3027432980 abstract "In the CORALLEEN trial, R+L achieved similar response rates to multi-agent CT. We present a comprehensive gene expression analysis done before, during, and after therapy to fully characterize the biology behind the primary results of the trial. CORALLEEN was a randomized study in postmenopausal women with stage I-IIIA hormone receptor positive (HR+)/HER2-negative Luminal B breast cancer by PAM50. Patients (pts) received either 6 cycles of R+L or 4 cycles of AC followed by 12 doses of paclitaxel. Primary endpoint was rate of PAM50 Risk of Relapse (ROR) low disease at surgery. Baseline, week 2, and surgical specimens were collected. Expression of 770 genes and 31 signatures were determined using the Breast360TM nCounter-based codeset. Response was defined as ROR-low disease at surgery, relative/absolute changes in ROR between baseline/week 2 and surgery, RCB-0/I or levels of Ki67 at surgery. To identify genes associated with response, a significance of microarrays (SAM) analysis with a false discovery rate (FDR) <5% was performed. A total 297/318 (93.4%) samples were available. No genes or signatures at baseline, or week 2, were found to be associated with response at surgery in each arm. At week 2, 146 (14.6%) genes or signatures were found significantly up-regulated (n=47) and down-regulated (n=99) in the R+L arm compared to CT. R+L induced higher expression of genes related to DNA damage repair and immune activation (e.g. TP53, RAD52, GZMM and CD19) and lower expression of cell-cycle and hormone-related genes (e.g. PGR, CDK1 and MKI67). At surgery, 102 (10.2%) genes or signatures were found significantly up-regulated (n=4) and down-regulated (n=98) in the R+L arm compared to CT. R+L induced higher downregulation of estrogen- and proliferation-related genes and signatures (e.g. PGR, ER signaling, and MKI67). No genes were able to predict response. Compared to CT, R+L induced higher downregulation of proliferation-related genes and signatures at week 2 and surgery. These results support the strategy to use the neoadjuvant setting to select patients who achieve a large molecular downstaging following CDK4/6 inhibition." @default.
• W3027432980 created "2020-05-29" @default.
• W3027432980 creator A5007895340 @default.
• W3027432980 creator A5011953075 @default.
• W3027432980 creator A5013368807 @default.
• W3027432980 creator A5014379154 @default.
• W3027432980 creator A5020050040 @default.
• W3027432980 creator A5042649658 @default.
• W3027432980 creator A5043895722 @default.
• W3027432980 creator A5048980172 @default.
• W3027432980 creator A5053983312 @default.
• W3027432980 creator A5061522111 @default.
• W3027432980 creator A5069211092 @default.
• W3027432980 creator A5070297345 @default.
• W3027432980 creator A5071763441 @default.
• W3027432980 creator A5077175788 @default.
• W3027432980 creator A5077763247 @default.
• W3027432980 creator A5080122151 @default.
• W3027432980 creator A5082195410 @default.
• W3027432980 creator A5089513581 @default.
• W3027432980 creator A5089703479 @default.
• W3027432980 date "2020-05-01" @default.
• W3027432980 modified "2023-10-10" @default.
• W3027432980 title "12P Gene expression profiling in early breast cancer treated with neoadjuvant ribociclib plus letrozole (R+L) versus chemotherapy (CT): A correlative analysis of the SOLTI-1402/CORALLEEN phase II trial" @default.
• W3027432980 doi "https://doi.org/10.1016/j.annonc.2020.03.148" @default.
• W3027432980 hasPublicationYear "2020" @default.
• W3027432980 type Work @default.
• W3027432980 sameAs 3027432980 @default.
• W3027432980 citedByCount "0" @default.
• W3027432980 crossrefType "journal-article" @default.
• W3027432980 hasAuthorship W3027432980A5007895340 @default.
• W3027432980 hasAuthorship W3027432980A5011953075 @default.
• W3027432980 hasAuthorship W3027432980A5013368807 @default.
• W3027432980 hasAuthorship W3027432980A5014379154 @default.
• W3027432980 hasAuthorship W3027432980A5020050040 @default.
• W3027432980 hasAuthorship W3027432980A5042649658 @default.
• W3027432980 hasAuthorship W3027432980A5043895722 @default.
• W3027432980 hasAuthorship W3027432980A5048980172 @default.
• W3027432980 hasAuthorship W3027432980A5053983312 @default.
• W3027432980 hasAuthorship W3027432980A5061522111 @default.
• W3027432980 hasAuthorship W3027432980A5069211092 @default.
• W3027432980 hasAuthorship W3027432980A5070297345 @default.
• W3027432980 hasAuthorship W3027432980A5071763441 @default.
• W3027432980 hasAuthorship W3027432980A5077175788 @default.
• W3027432980 hasAuthorship W3027432980A5077763247 @default.
• W3027432980 hasAuthorship W3027432980A5080122151 @default.
• W3027432980 hasAuthorship W3027432980A5082195410 @default.
• W3027432980 hasAuthorship W3027432980A5089513581 @default.
• W3027432980 hasAuthorship W3027432980A5089703479 @default.
• W3027432980 hasBestOaLocation W30274329801 @default.
• W3027432980 hasConcept C104317684 @default.
• W3027432980 hasConcept C121608353 @default.
• W3027432980 hasConcept C126322002 @default.
• W3027432980 hasConcept C143998085 @default.
• W3027432980 hasConcept C150194340 @default.
• W3027432980 hasConcept C168563851 @default.
• W3027432980 hasConcept C18431079 @default.
• W3027432980 hasConcept C185592680 @default.
• W3027432980 hasConcept C203092338 @default.
• W3027432980 hasConcept C530470458 @default.
• W3027432980 hasConcept C55493867 @default.
• W3027432980 hasConcept C71924100 @default.
• W3027432980 hasConceptScore W3027432980C104317684 @default.
• W3027432980 hasConceptScore W3027432980C121608353 @default.
• W3027432980 hasConceptScore W3027432980C126322002 @default.
• W3027432980 hasConceptScore W3027432980C143998085 @default.
• W3027432980 hasConceptScore W3027432980C150194340 @default.
• W3027432980 hasConceptScore W3027432980C168563851 @default.
• W3027432980 hasConceptScore W3027432980C18431079 @default.
• W3027432980 hasConceptScore W3027432980C185592680 @default.
• W3027432980 hasConceptScore W3027432980C203092338 @default.
• W3027432980 hasConceptScore W3027432980C530470458 @default.
• W3027432980 hasConceptScore W3027432980C55493867 @default.
• W3027432980 hasConceptScore W3027432980C71924100 @default.
• W3027432980 hasFunder F4320321411 @default.
• W3027432980 hasFunder F4320332999 @default.
• W3027432980 hasLocation W30274329801 @default.
• W3027432980 hasOpenAccess W3027432980 @default.
• W3027432980 hasPrimaryLocation W30274329801 @default.
• W3027432980 hasRelatedWork W1981379144 @default.
• W3027432980 hasRelatedWork W2098891062 @default.
• W3027432980 hasRelatedWork W2114239030 @default.
• W3027432980 hasRelatedWork W2180467298 @default.
• W3027432980 hasRelatedWork W2294069589 @default.
• W3027432980 hasRelatedWork W2334745504 @default.
• W3027432980 hasRelatedWork W2993943323 @default.
• W3027432980 hasRelatedWork W3132043293 @default.
• W3027432980 hasRelatedWork W377899687 @default.
• W3027432980 hasRelatedWork W4313880178 @default.
• W3027432980 hasVolume "31" @default.
• W3027432980 isParatext "false" @default.
• W3027432980 isRetracted "false" @default.
• W3027432980 magId "3027432980" @default.
• W3027432980 workType "article" @default.